Introduction
Lysosomal disease encompasses a wide spectrum of rare genetic disorders with defects in proteins essential for normal function of the lysosomal system (Platt and Walkley 2004) . Most lysosomal diseases show widespread tissue and organ involvement, with brain, viscera, bone and connective tissues often being affected. Brain disease is particularly prevalent, involving two-thirds of all lysosomal diseases. Here, clinical disease may be manifest as mental retardation and/or dementia, sensory loss including blindness or deafness, motor system dysfunction, seizures, sleep and behavioural disturbances, and so forth. Lysosomal diseases are progressive, and ultimately fatal, disorders but affected individuals generally appear normal at birth and develop clinical disease only years or decades later. The disease course can be highly variable even among affected siblings in the same family, and more often than not clear-cut genotype-phenotype correlations have not been established. That such multifaceted and serious disease conditions result from simple inborn errors of metabolism raises the persisting question of why these disorders are ultimately so clinically complex. A predominate early view to explain lysosomal disease pathogenesis emanated from the original concept that these disorders are caused by individual lysosomal enzyme deficiencies followed by accumulation of a single major substrate normally degraded by that enzyme (Hers 1965) . Following the build-up of this non-degraded primary substrate, the endosomal/lysosomal (E/L) system would eventually be overwhelmed, normal cell functions would collapse, and cells would simply die as a result of this progressive constipation. This so-called Fcytotoxicity hypothesis_ (Desnick et al 1976) is still often cited today to explain the pathogenesis of lysosomal disease, yet modern developments in cell biology and neuroscience offer much richer avenues of explanation. For lysosomal diseases affecting brain, for example, four central themes can be recognized as setting the stage for this complexity in pathogenic cascades. These are based on: (i) the wide variety of enzyme and nonenzyme proteins implicated in causing lysosomal disease and the many ways defects in their expression or function can compromise the lysosomal system; (ii) the complexity of the brain itself in terms of heterogeneity of the neuronal and glial cell types that typically exhibit distinct metabolic identities and interrelationships; (iii) the potential roles of the greater E/L system in signal transduction and (iv) in cellular homeostatic control, and the consequences following compromise in these functions in lysosomal disease.
Defective proteins causing lysosomal disease are widely varied in function and location
The range of molecular defects causing lysosomal compromise in lysosomal disease is extensive and involves both soluble and membrane-associated proteins (Platt and Walkley 2004) . Indeed, defects in no fewer than 50 different proteins have been implicated to date as causing lysosomal dysfunction, and new proteins linked to lysosomal disease continue to be identified. While most are enzymes with acidic pH optima consistent with the original lysosomal disease concept, many others are not. Included here, for example, are enzymes in the Golgi/TGN or ER that are responsible for trafficking and catalytically activating specific lysosomal enzymes. Defects in these proteins cause mucolipidosis (ML) II/III and multiple sulfatase deficiency (MSD), respectively. Lysosomal diseases are also caused by defects in soluble and membrane-associated non-enzyme proteins of late endosomes and lysosomes believed essential for the processes of substrate degradation and egress, as well as vesicle fusion. Examples of soluble proteins are prosaponin and its processed components, saposins A-D, and the G M2 activator protein (G M2 -AP), all of which are critical for aiding in the enzymatic degradation of glycolipid substrates. The soluble protein NPC2 is believed critical for cholesterol egress, but so too is the membrane-associated NPC1 protein, as discussed below.
The complexity of the molecular underpinnings of lysosomal disease is typified by conditions like G M2 gangliosidosis and Niemann-Pick diseases. G M2 gangliosidosis can be caused by defects in b-hexosaminidase (composed of two subunits, a and b, coded for by two different genes) or by defects in the G M2 -AP. Hence the occurrence of Tay-Sachs (a subunit defect), Sandhoff (b-subunit defect) or the AB-variant (G M2 -AP defect) diseases, all of which nonetheless manifest as G M2 gangliosidosis. Niemann-Pick diseases are similarly complex (Walkley and Suzuki 2004) . Type C disease, originally named for its clinical similarity to Niemann-Pick A/B disease, was later found not to exhibit a primary defect in sphingomyelinase as occurs in A/B disease, but rather to be due to defects in the aforementioned cholesterol-binding proteins (NPC1 or NPC2) of the late endosome. Interestingly, the NPC1 and 2 proteins are dramatically different, one being a transmembrane protein (NPC1) of late endosomes, the other a soluble protein (NPC2) in the lumen of late endosomes. When either protein is defective, the same apparent cholesterol storage condition ensues, believed to be caused by a block in retroendocytic trafficking of cholesterol out of late endosomes to other sites in the cell (Pentchev et al 1994) . Cholesterol storage is accompanied by accumulation of both acidic and neutral glycosphingolipids (GSLs) (G M2 and G M3 gangliosides; also lactosylceramide). And while unesterified cholesterol is typically viewed as the primary storage material in Niemann-Pick C disease, experiments limiting expression of complex gangliosides lead to significant reductions in the extent of cholesterol sequestration in most neurons (Gondré -Lewis and Walkley 2003) . This suggests that the NPC1 and NPC2 proteins may also be associated with retroendocytic trafficking of GSLs. Interestingly, cholesterol sequestration in neurons is also prominent in the G M1 and G M2 gangliosidoses, but here clearly occurs secondarily to the primary storage of gangliosides. Like NPC1 and NPC2 described above, defects in other enigmatic proteins have similarly been linked to lysosomal disease. For example, mutations in the MCOLN1 gene, which codes mucolipin-1, an E/L ion channel protein belonging to the mucolipin subfamily of transient receptor potential (TRP) proteins, causes mucolipidosis type IV (ML IV) disease (Zeevi et al 2007) . In spite of its name, ML IV has little connection other than historic with ML II/III diseases which are caused by defects in the phosphotransferase enzyme responsible for adding the mannose 6-phosphate moiety to lysosomal enzymes as required for normal targeting to lysosomes. Like NPC1, mucolipin-1 resides in the membrane of late endosomes/lysosomes and, while it is implicated in lysosomal pH control and in membrane fusion/fission events, its function remains essentially unknown. A similar situation exists for many of the proteins implicated in the ten (CLN1-CLN10) so-called neuronal ceroid lipofuscinoses, or Batten diseases (Kyttä lä et al 2006) . The CLN3 protein, for example-defects in which cause juvenile Batten disease-may be associated with autophagolysosome fusion/maturation (Cao et al 2006) , lysosomal pH control (Pearce et al 1999) , or a host of other functions (Rakheja et al 2008) . Similarly, the CLN6 and CLN8 proteins are believed to be localized to membranes of the ER and, while their absence leads to lysosomal storage, their functional link to lysosomes is unknown (Kyttä lä et al 2006) .
It is evident from the above, brief overview that defective proteins in lysosomal diseases vary widely and the consequences of their functional loss are often not understood (Platt and Walkley 2004) . While identification of primary substrates has provided insight into identification of lysosomal enzyme defects, when lysosomal diseases are caused by proteins responsible for other functions-such as lysosomal pH control (as an example)-primary substrates may be heterogeneous. Yet even for lysosomal hydrolase defects the materials accumulating in the E/L system are also remarkably heterogeneous. Numerous gangliosides, for example, accumulate in neurons in most of the mucopolysaccharidoses (MPSs) even though the enzymes defective in these conditions are known to act on glycosaminoglycan (GAG) degradation and not GSLs (Neufeld and Muenzer 2001) . Secondary inhibition of GSL degradative enzymes by the primary GAG storage has been hypothesized, but the sequestered gangliosides (G M2 and G M3 ) do not typically localize with each other, or with GAG storage (McGlynn et al 2004) . Unesterified cholesterol also accompanies this storage in MPS disease, possibly secondary to the gangliosides and in a manner similar to what occurs in G M2 gangliosidosis described above. Remarkably, ganglioside and cholesterol storage also occurs in brain in the glycoproteinosis known as a-mannosidosis, again without explanation (Walkley 2004a, b) . Secondary storage of glycolipids and related materials is actually the rule rather than the exception in lysosomal disease, and likely contributes significantly to compromise in cell function, as described below.
Lysosomal diseases often exhibit selective neuronal and glial involvement
While some lysosomal diseases, like Niemann-Pick type C, exhibit storage and related consequences in cells throughout the brain, other diseases exhibit a much more restricted distribution. Examples of this selective vulnerability to lysosomal dysfunction abound. Fabry disease, for example, in terms of CNS involvement, has long been known to show storage of its primary substrate (globotriaosylceramide) largely limited to scattered neurons in the spinal cord, brainstem, amygdala, hypothalamus and entorhinal cortex (deVeber et al 1992) . In neuropathic Gaucher disease, storage in neurons is minimal to absent, but storage in cells of monocyte/macrophage lineage, the so-called Gaucher cells, is prominent (Beutler and Grabowski 2001) . In Krabbe disease, like Gaucher disease, neuronal storage is not evident and the presence of swollen macrophages (globoid cells) predominates (Wenger et al 2001) . In addition there is widespread death of oligodendroglia, possibly secondary to the build-up of the toxic compound, psychosine, leading to myelin deficits (demyelination) and in resulting clinical disease. Most lysosomal diseases also exhibit activation of microglia and the debate is ongoing as to whether this activation is caused by metabolic events intrinsic to microglia (and therefore inappropriate) or, alternatively, is in direct and appropriate response to abnormalities in neurons (altered surface expression of gangliosides, apoptotic or necrotic death, etc.). Understanding of events triggering inflammation is of major importance since therapies directed at ameliorating microglial activation presumably could be beneficial in some circumstances but possibly detrimental in others. Such events may also vary as lysosomal diseases progress.
In some lysosomal diseases, primary storage in neurons is widespread but restricted cell populations selectively exhibit secondary accumulation of additional compounds. For example, in the glycoproteinosis a-mannosidosis, mentioned earlier, storage of characteristic mannose-rich oligosaccharides is widespread and affects all cells, but secondary storage of GSLs is a conspicuous feature of select subpopulations of cortical pyramidal neurons and some GABAergic intrinsic neurons (Walkley 2004a, b) . These ganglioside-sequestering cortical pyramidal neurons have been shown to sprout ectopic dendrites in a manner similar to what happens to essentially all cortical pyramidal neurons in primary G M1 and G M2 gangliosidosis. This growth of ectopic dendrites, a phenomenon unique to lysosomal disease, is always found to be limited to GSL-storing cortical pyramidal neurons and multipolar neurons in the claustrum and amygdala (Walkley 2003 (Walkley , 2004a Walkley et al 2000) .
Just as cortical pyramidal neurons selectively show the presence of renewed dendrite growth in some lysosomal diseases, other neurons exhibit unusual axonal alterations known as neuroaxonal dystrophy or axonal spheroid formation (Walkley 2004a; Walkley et al 1991) . Spheroid formation appears detrimental to neurons, since Purkinje cells, which appear particularly vulnerable to spheroid formation, also tend to die early in the disease process. Ultrastructural studies have revealed that spheroids are not composed of materials like those accumulating in perikarya (membranous cytoplasmic bodies, zebra bodies, etc.), but rather consist of collections of tubulovesicular profiles, mitochondria, and autophagosomal-like and multivesicular-type bodies. This ultrastructure is similar from one storage disease to the next, consistent with a generic cause for their formation (Walkley 2004a) . The incidence and distribution of spheroids correlate closely with the onset and type of motor system defects exhibited by affected animals, suggesting that they are a major player in generating neurological dysfunction. Spheroids are readily visualized in neurons using immunocytochemistry to label components trafficked in axons, including enzymes (glutamic acid decarboxylase) as well as calcium-binding proteins (parvalbumin, calbindin). Using these cell selective markers, spheroids were found to occur most commonly on GABAergic neurons, including Purkinje cells, neurons in basal ganglia, and nonpyramidal (intrinsic) cells of cerebral cortex. Spheroids are well documented in lysosomal disorders, where they are found in abundance in primary ganglioside storage diseases, Niemann-Pick disorders (types A and C), and in the glycoproteinosis a-mannosidosis. In other lysosomal diseases, most notably the early-onset neuronal ceroid lipofuscinoses (CLN1 and CLN2 diseases), spheroid formation is not characteristic, but widespread neuron death in cerebral cortex is a common occurrence. Thus whether the result of the primary metabolic event or a downstream consequence in the disease cascade, selective neuronal vulnerability in lysosomal disease is a characteristic finding. This feature of lysosomal disease undoubtedly reflects significant differences in the metabolic signatures of individual types of neurons comprising the complex neuronal networks of the brain. Eventually it should be possible to use the presence of these specific disease features to gain insight into the specialized characteristics of normal neurons. Ectopic dendritogenesis, for example, suggests the presence of a unique capacity for dendritic plasticity in the affected pyramidal cell populations in cerebral cortex, amygdala and claustrum. Understanding what is being triggered in lysosomal disease to cause a renewal of dendritic sprouting and associated synapse formation may provide novel insight into broader mechanisms underlying learning and memory in normal brain.
The role of the E/L system in signal transduction events
Not only has our understanding of the complexity of lysosomal diseases and their defects expanded significantly in recent years, so too has knowledge of the role of the E/L system in overall cell function (Pol and Di Fiore 2006) (Fig. 1) . In addition to being involved in regulating the composition of neuronal membranes and in internalizing receptor-ligand complexes, endocytosis also plays a critical role in attenuating and integrating a wide variety of signalling events affecting many cellular functions. In neurons, endocytic events similarly govern a variety of signalling mechanisms, with some like those associated with neurotransmitter actions, being unique to these types of cells. For example, endocytic mechanisms are known to control the availability of neurotransmitter receptors at excitatory synapses. AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid) receptors, which regulate the majority of fast excitatory neurotransmission and are therefore critical for synaptic plasticity, are known to undergo rapid constitutive internalization as a consequence of synaptic activity. Once internalized, AMPA receptors are sorted from early endosomes either to specialized recycling endosomes for reinsertion in the plasmalemma or are trafficked to late endosomes for fusion with lysosomes and resulting elimination (Barry and Ziff 2002; Bredt and Nicoll 2003) . In contrast, the constitutive internalization of NMDA (N-methyl-D-aspartate) and metabotropic glutamate receptors (mGluRs) is less prominent. Subunits forming AMPARs (GluR1-4) are well documented to assemble as homo-or hetero-dimers, with subunit composition being critical for their functional properties. The GluR2 subunit, unlike GluR1, 3 and 4, is Ca 2+ -impermeable, making it the key determinant of AMPAR function (Isaac et al 2007) . Importantly, overexpression of the GluR2 subunit in cultured neurons induces ectopic dendritic spine formation, consistent with AMPA receptor expression and localization playing a major role in dendrite and synapse plasticity (Passafaro et al 2003) . These findings suggest that the E/L system-to the extent that it influences AMPA receptor availability-is poised to exert significant influence over dendritic plasticity. That many lysosomal diseases are characterized by ectopic dendritogenesis raises important questions about possible compromise in AMPA receptor cycling secondary to lysosomal system compromise (Walkley 2007 ).
In addition to a possible compromise of neurotransmitter receptor recycling, another prominent aspect of signalling that may be altered in lysosomal disease involves growth factors. Growth factor receptors are known to be internalized by endocytosis, with this occurring both in the somatodendritic as well as axonal domains, with signalling events varying according to the specifics of the endocytic route and vesicle type (Bronfman et al 2007) . Importantly, studies have shown that growth factors such as BDNF, a TrkB ligand, when applied to young cortical neurons can cause exuberant dendrite growth (McAllister 2001) . As in the example of AMPA receptor trafficking and the E/L system described above, this observation raises the question whether growth factor signalling might be abnormal in lysosomal disease as a way to account for the abnormal growth of dendrites. Growth factors are also endocytosed at synaptic terminals and transported along with their receptors back to the neuronal cell body for signalling (Bronfman et al 2007) . These retrogradely transported vesicles are often referred to as signalling endosomes because they contain ligand-bound Fig. 1 Schematic summarizing the concept of the lysosome as a central element in the greater lysosomal system of neurons with links to the endocytic streams from somatodendritic and axonal domains, and to the macroautophagy stream and its close allies, the ubiquitin-proteosomal system (UPS) and chaperone-mediated autophagy (CMA) components. What flows into this system must also leave in some form, depicted here as the salvage pathway with delivery to the Golgi/TGN, mitochondria, and other sites in the cell. The complexity of the disease cascades in lysosomal disorders is conjectured to emanate in part from disruption of these interrelated components of the greater lysosomal system, as described in the text. EE, early endosome; RE, recycling endosome; LE, late endosome; LY, lysosome; SE, signalling endosome; AV, autophagic vacuole; ER, endoplasmic reticulum) growth factor receptors derived from postsynaptic sites that are being transported back to the cell body where they are believed to recruit appropriate secondmessenger cascades for signal transduction purposes (Howe and Mobley 2005) . The prominence of spheroids in axons of Purkinje cells, described earlier, and the finding that these cells are prone to die early in many storage diseases have suggested that the spheroids themselves may be contributing to this early demise by causing a block in signalling endosomes carrying a growth factor-receptor complex essential for cell survival (Walkley 2004a) . Thus signalling events in lysosomal disease may be exaggerated, as suggested by the occurrence of ectopic dendritogenesis, or compromised, as suggested by Purkinje cell death following spheroid formation. Clearly these features of lysosomal disease pathogenesis deserve further investigation.
The 'greater lysosomal system' as a central metabolic coordinator
It can be argued that the primary goal of lysosomal processing is the degradation and recycling of breakdown products for biosynthetic purposes, a process aptly referred to as Fmetabolic salvage_ (Tettamanti et al 2003) (Fig. 1) . For some of these byproducts of lysosomal catabolism, e.g., free sialic acid and cystine, specific transport proteins have been identified (sialin and cystinosin, respectively) whose importance is made apparent by diseases caused by their absence (Platt and Walkley 2004 ). Yet there is ample evidence that some complex molecules processed by the E/L system do not have to be degraded to their simplest components prior to exit from these organelles. Prime examples are gangliosides, which are synthesized in the Golgi/TGN and delivered to the cell surface by vesicular transport in exocytic vacuoles, followed by insertion in the outer leaflet of the plasmalemma, where they reside in close association with membrane raft-related molecules including cholesterol, sphingomyelin, and various GPI-anchored proteins (Kolter and Sandhoff 2005; Schwarzmann and Sandhoff 1990) . Following endocytosis, complex gangliosides come into contact with an array of hydrolytic enzymes and activator proteins that facilitate their catabolism to monosialogangliosides (e.g., G M1 ). Subsequently, G M1 is degraded to G M2 by lysosomal b-galactosidase, and G M2 to G M3 by lysosomal b-hexosaminidase (in conjunction with the G M2 -AP), with defects at either of these degradative steps leading to G M1 and G M2 gangliosidosis, respectively. Numerous studies on the fate of less complex gangliosides (G M2 and G M3 , as well as G M1 ) and of additional breakdown products of gangliosides (neutral glycosphingolipids known as lactosylceramide and glucosylceramide) indicate that they may be recycled (or Fsalvaged_) after endocytosis prior to their complete degradation (Tettamanti et al 2003) . Thus, gangliosides like G M2 and G M3 may exit the E/L system and be trafficked to the Golgi/TGN, where they would be reglycosylated and delivered again to the plasmalemma. Importantly, this suggests that there are two potential routes available to monosialogangliosides as they transit through the lysosomal system-one involving direct recycling to the Golgi/TGN and the other leading to full lysosomal degradation.
Given the above, an emerging question of central importance for lysosomal disease is: What are the consequences of a failure to recycle material (e.g., monosialogangliosides, cholesterol, GAGs, and others) out of the E/L system? This question would be easier to answer if there were greater understanding of the function of gangliosides in neurons, or if the relationship between GAG recycling and proteoglycan synthesis and function were clearly defined, or if the routes of trafficking of unesterified cholesterol within neurons or between neurons and astrocytes were fully known. But even with these significant limitations, several scenarios concerning this apparent Ffailure to recycle_ can be considered. The first of these, as stated earlier, is that lysosomal storage simply overwhelms the cell_s capacity for volume expansion and causes death as a consequence. A second possibility gaining strength with recent publications is that sequestered substrates like G M1 ganglioside in G M1 gangliosidosis might Fleak_ into membrane domains normally containing little or no ganglioside, like the ER, resulting in depletion of Ca 2+ stores, activation of the ER stress response, and eventually apoptosis and neuron death (d_Azzo et al 2006) . Similarly, in G M2 gangliosidosis it has been shown that increases of G M2 in microsomal membranes inhibit the activity of SERCA, which could similarly cause ER stress and apoptosis (Ginzburg et al 2004) . Parallel events in dysregulation of intracellular stores of Ca 2+ secondary to inappropriate ganglioside build-up in internal cell membranes may similarly be occurring in Gaucher, Niemann-Pick A, and other lysosomal diseases. Changes in ganglioside expression or availability at the plasmalemma may also be occurring, followed by alteration in surface receptor expression (e.g., of toll-like receptors) and microglial activation (Jou et al 2006) .
While the above events may prove of significant impact in lysosomal disease, these conditions nonetheless are typically chronic and most neurons exist for many years in the face of slowly progressive lysosomal storage. Thus, to a great extent, pathogenic cascade events that are occurring are not acutely cytotoxic. They also likely are highly varied across the spectrum of lysosomal disease. For example, recent studies show that the brains of mice lacking the NPC1 protein and developing cholesterol/GSL storage typical of Niemann-Pick C disease are deficient in the neurosteroid allopregnanolone (Griffin et al 2004) . Since allopregnanolone is a neurosteroid requiring cholesterol for synthesis, this finding has been interpreted as suggesting that the block in cholesterol movement out of late endosomes to mitochondria (where the synthetic enzymes for allopregnanolone production are found) is responsible for this deficit. Such findings have also suggested a possible new form of therapy based on byproduct replacement, in which missing compounds are administered (Griffin et al 2004; Walkley 2007) . Allopregnanolone may be but one example of a metabolic product deficit occurring secondary to lysosomal storage. Indeed, GSLs may represent a second class of compounds impacted by sequestration of metabolic precursors, as suggested many years ago by Sandhoff and colleagues (Schwarzmann and Sandhoff 1990) . As it has been estimated that as much as 70% of the GSL pool in neurons is salvaged prior to complete degradation in the E/L system, the sequestration of simple gangliosides (G M1 , G M2 , G M3 ) in lysosomal disease may result in a deficit of precursor material in the Golgi/TGN for renewal of complex gangliosides at the plasmalemma. One consequence of such an event might be for the neuron to up-regulate GSL synthesis, an event that could in turn alter the expression of specific gangliosides or related components of membrane rafts in the plasmalemma. Enhanced GSL synthesis, if it occurred, likely would not solve the neuron_s deficit, however, but rather would simply add further to the storage process.
Yet another solution to metabolic precursor deficits might be for the neuron to Fmine_ resources within the cell through a mechanism known as macroautophagy (autophagy) (Fig. 1) . Recent studies have shown that maintenance of a basal level of autophagy is critical for normal neuronal function (Hara et al 2006; Komatsu et al 2006) , so in this respect they are not really different from other cells in which starvationinduced stress elicits autophagy (Cuervo 2004) . Macroautophagy is also closely allied to protein degradative mechanisms associated with chaperone-mediated autophagy (CMA) and the ubiquitin-proteosomal system (UPS). The involvement of autophagy, as well as possible CMA and UPS defects, has recently come under increased focus in lysosomal disease Settembre et al 2008; Tayebi et al 2003) . In terms of autophagy, current reports support the possibility that autophagy is blocked as a general feature of lysosomal storage or, alternatively, is increased. Blockage in autophagy clearly would be detrimental to neurons, but similarly, if autophagy were increased, this again might not be beneficial since ultimately the same catabolic defect, in the case of lysosomal enzyme deficiencies, would limit access to the stored GSLs. In the case of NiemannPick C disease or other putative substrate traffickingtype defects, however, autophagy might offer an alternative route for allowing interaction between sequestered GSLs and normal catabolic enzymes present in lysosomes. That is, autophagy could, conceivably, be playing a role in partially ameliorating storage in some lysosomal diseases. If so, pharmacological enhancement of autophagy might provide additional benefit, as recently suggested for Huntington disease (Ravikumar and Rubinsztein 2006) .
Whether the neuron is increasing activity in synthetic pathways or enhancing autophagy in an effort to overcome lysosomal storage, such actions would be expected to be energy-consuming. Interestingly, recent studies have demonstrated that mouse models of lysosomal disease exhibit reduced fat stores unrelated to compromise of food intake, consistent with the presence of an energy-consuming process inherent in these diseases (Woloszynek et al 2007) . As a whole, these studies illustrate the array of events that might contribute to the complex disease cascades in lysosomal disease and raise the interesting question whether these disorders are more appropriately viewed as disease-induced states of Fstarvation stress_-that is, as conditions characterized by deficiency, rather than overabundance (storage).
Conclusions
Growth of knowledge about lysosomal disease mirrors the modern advance of medicine begun by Garrod with the discovery of inborn errors of metabolism (Garrod 1909) . Over the past century there have been eras focused on clinical descriptions, on biochemical characterization of enzyme defects and primary storage materials and, most recently, on gene and mutation analysis. Now, it can be declared, we have entered a new era, one that draws on all of these earlier discoveries and begins to address, in detail, the disordered events in cell biology brought about by individual lysosomal system defects-the era of lysosomal disease pathogenesis. Clearly, a wide array of protein defects leads to metabolic compromise and storage in lysosomal disease, with these events in turn driving the development of specific cellular pathologies depending on the cells affected and their metabolic signatures. Disruption of E/L function in neurons has the capacity to compromise many normal cell operations and to generate a host of downstream consequences, from the growth of ectopic dendrites to formation of axonal spheroids, to neuron death, and so forth. Failure to recycle materials out of the E/L system in lysosomal disease may also lead to deficiency of precursor pools of metabolites and thereby alter cellular homeostatic functions leading to changes in synthetic pathways and/or to autophagy in an effort to overcome these deficits. Analysis of these complex pathogenic cascades in lysosomal disease will offer new insights into therapy as well as the opportunity to more fully appreciate the role of the greater lysosomal system in cells of the normal nervous system.
